Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
INCYTE CORP executive reports routine tax withholding share disposition. EVP, GM Dermatology US Matteo Trotta had 537 shares of common stock withheld at a price of $92.23 per share to cover tax obligations tied to previously granted restricted stock units. After this automatic withholding, he directly holds 14,882 common shares. Footnotes state that this figure includes 11,160 shares underlying restricted stock units that are not yet vested.
Incyte Corporation announced several executive leadership changes. Pablo J. Cagnoni was appointed President, Incyte and Global Head of Research and Development, adding broader enterprise-wide strategic and operational responsibilities while continuing to lead R&D. Steven H. Stein became Executive Vice President, Chief Medical Officer and Head of Late-stage Development, continuing to oversee late-stage programs in Hematology, Oncology and Immunology and Global Medical Affairs.
Mohamed Issa was appointed Executive Vice President and Head of U.S. Commercial, continuing to lead U.S. Oncology and taking on expanded responsibility for U.S. Immunology as these businesses are integrated into a single U.S. commercial organization. William J. Meury remains Chief Executive Officer and a member of the Board, while Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. The filing states there were no changes to compensation arrangements for the impacted executives in connection with these title changes.
INCYTE CORP President, R&D Pablo J. Cagnoni exercised stock options and then sold shares in a routine liquidity transaction. He exercised options to acquire 7,166 shares of common stock at $61.18 per share and 11,501 shares at $64.25 per share, totaling 18,667 shares. On the same day, he sold 18,667 common shares at an average price of $94.24 per share. After these transactions, his reported direct ownership was 234,800 common shares, which the notes state includes 229,661 shares underlying previously reported unvested restricted and performance stock units.
INCY reports a Form 144 notice for the sale of 18,667 shares of Common Stock via a stock option exercise on 03/17/2026. The filing lists proceeds of 1,759,101.55 and shows prior sales in the past three months associated with Pablo Cagnoni. The transaction is reported through Morgan Stanley Smith Barney LLC as broker-dealer.
Incyte Corporation reported that on February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for the supplemental Biologics License Application for Zynyz (retifanlimab-dlwr) injection in metastatic non-small cell lung cancer in combination with platinum-based chemotherapy.
The FDA’s letter cited regulatory compliance inspection findings at Catalent Indiana, the third-party fill-finish facility referenced in the application, as the sole approvability issue. The FDA did not raise concerns about Zynyz’s efficacy, safety data in NSCLC, or the third-party drug substance manufacturer. Incyte is working with the FDA and Catalent Indiana to address the letter and support a potential resubmission.
INCYTE CORP President, R&D Pablo J. Cagnoni reported multiple equity transactions. On February 19, 2026, he exercised employee stock options into 13,093 and 5,575 shares of common stock at exercise prices of $61.76 and $61.18 per share, respectively, through derivative conversions.
He then executed an open-market sale of 18,668 shares of common stock at an average price of $100.91 per share. After these transactions, he directly owned 234,800 shares of common stock, plus remaining stock options, and had an additional 229,661 shares tied to unvested restricted and performance stock units.
Baker Bros. Advisors and affiliates filed Amendment No. 32 to their Schedule 13D on Incyte Corp., updating their large ownership position and related rights. The filing reports beneficial ownership of up to 31,213,417 shares of Incyte common stock by certain reporting persons, representing 15.7% of the outstanding shares as of February 3, 2026, including 108,931 vested stock options held by Julian C. Baker as director compensation.
The amendment also discloses a February 6, 2026 Registration Rights Agreement giving the Baker-managed funds resale registration rights for all of their Incyte securities. Incyte must, upon request, file and maintain a resale shelf registration and permit limited underwritten offerings and block trades for up to ten years, enhancing flexibility for future sales by the funds.
Incyte Corporation is a global biopharmaceutical company focused on hematology, oncology, and inflammation and autoimmunity. It discovers, develops and commercializes proprietary therapies from hubs in Wilmington, Delaware, Europe, Japan and Canada.
In hematology, key products include JAKAFI/JAKAVI (ruxolitinib) for myelofibrosis, polycythemia vera and graft-versus-host disease, ICLUSIG for certain leukemias, MONJUVI/MINJUVI for diffuse large B‑cell lymphoma and follicular lymphoma, and NIKTIMVO for chronic graft-versus-host disease. The company highlights strong reliance on JAKAFI/JAKAVI revenue as a principal risk.
In oncology, Incyte markets PEMAZYRE for cholangiocarcinoma and myeloid/lymphoid neoplasms with FGFR rearrangements, and ZYNYZ for Merkel cell carcinoma and squamous cell carcinoma of the anal canal. In inflammation and autoimmunity, OPZELURA (ruxolitinib cream) is approved for atopic dermatitis and nonsegmental vitiligo, with additional late-stage programs in hidradenitis suppurativa, vitiligo, prurigo nodularis and asthma via oral JAK1 inhibitor povorcitinib.
Incyte expands its portfolio with late-stage assets such as mutant CALR antibody INCA033989 for essential thrombocythemia and myelofibrosis, KRAS G12D inhibitor INCB161734, CDK2 inhibitor INCB123667, and TGFβR2xPD‑1 bispecific INCA33890. Strategic collaborations with Novartis, Lilly, Syndax, MacroGenics and others provide milestones and royalties, while a broad patent estate and regulatory exclusivities protect major products into the 2030s.
Incyte reported strong growth for Q4 and full-year 2025 and set higher 2026 revenue targets. Total revenue reached $1.51 billion in the fourth quarter, up 28% year over year, and $5.14 billion for 2025, up 21%, driven mainly by a 20% increase in net product revenue to $4.35 billion.
Key brands Jakafi and Opzelura grew solidly, while newer oncology products Niktimvo and Zynyz contributed increasing sales. GAAP net income jumped to $1.29 billion for 2025, with diluted EPS of $6.41, reflecting both higher revenue and the absence of large one-time R&D charges recorded in 2024.
For 2026, Incyte guides total net product revenue to $4.77–$4.94 billion, including Jakafi of $3.22–$3.27 billion, Opzelura of $750–$790 million, and hematology/oncology products of $800–$880 million. The company also plans substantial R&D and SG&A investment while advancing multiple late-stage trials and preparing for potential new launches.